Skip to main content
Premium Trial:

Request an Annual Quote

Philip Padou, Sandra Benson

Premium
Philip Padou, who had been on Bio-Rad’s board since 1980, passed away, the company announced late last week. Padou, who retired as vice president and CFO from Ozier Perry and Associates, a risk assessment software and consulting from in 1991, passed away during New Year’s weekend.
 

 

Miraculins announced this week that Sandra Benson is the company’s manager of investor relations. Benson had been with Investors Group and BMO Financial Group. In her new job, she will aim to strengthen communication with current and potential shareholders while increasing awareness of the company throughout the financial and investment community and media, Miraculins said in a statement. 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.